title: Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Cinzia
authors.initials: C
authors.lastname: Pellegrini
authors.forename: Alessandro
authors.initials: A
authors.lastname: Broccoli
authors.forename: Vittorio
authors.initials: V
authors.lastname: Stefoni
authors.forename: Letizia
authors.initials: L
authors.lastname: Gandolfi
authors.forename: Federica
authors.initials: F
authors.lastname: Quirini
authors.forename: Lisa
authors.initials: L
authors.lastname: Argnani
authors.forename: Emilio
authors.initials: E
authors.lastname: Berti
authors.forename: Enrico
authors.initials: E
authors.lastname: Derenzini
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide